www.rinvoq.com
Open in
urlscan Pro
2600:9000:223e:9600:5:8ced:94c0:93a1
Public Scan
Submitted URL: http://compareinsurancechart.com/
Effective URL: https://www.rinvoq.com/resources/landing/insurance-comparison-chart?cid=olm_br_imm_ps_roe_icc_olm_icc_0062_202108
Submission: On December 16 via api from TR — Scanned from DE
Effective URL: https://www.rinvoq.com/resources/landing/insurance-comparison-chart?cid=olm_br_imm_ps_roe_icc_olm_icc_0062_202108
Submission: On December 16 via api from TR — Scanned from DE
Form analysis
1 forms found in the DOMPOST
<form id="fileUploadForm" enctype="multipart/form-data" method="post" target="fileUploadIframe"><input type="file" id="fileSelector" name="file" style="display: none;"><input name="filename" type="hidden"></form>
Text Content
Learn how AbbVie could help you save on RINVOQ. Call 1-800-2RINVOQ or click to learn more > Skip to Main content * Important Safety Information * Full Prescribing Information & Patient Information * Full Prescribing Information (English) * Medication Guide * Healthcare Professionals Site * View All Conditions * 1-800-2RINVOQ * Cost & Savings * Sign up for RINVOQ updates * * Choose your Condition * Moderate to Severe Eczema (Atopic Dermatitis)* * Moderate to Severe Rheumatoid Arthritis * Active Psoriatic Arthritis * Active Ankylosing Spondylitis * Active Non-radiographic Axial Spondyloarthritis * Moderate to Severe Ulcerative Colitis * Moderate to Severe Crohn’s Disease * Not well controlled with other pills or injections, including biologics. * When TNF blockers did not work well or could not be tolerated. * RINVOQ Resources * About RINVOQ Complete * Save on RINVOQ * Your Nurse Ambassador * RINVOQ Complete App * Preparing for RINVOQ * Insurance Explained * Building Your Routine * *Not well controlled with other pills or injections, including biologics. * When TNF blockers did not work well or could not be tolerated. * 1-800-2RINVOQ * Cost & Savings * Sign up for Rinvoq updates * * Important Safety Information * Full Prescribing Information & Patient Information * Full Prescribing Information (English) * Medication Guide * Healthcare Professionals Site * View All Conditions IMPORTANT SAFETY INFORMATION & USES Warning: Serious Infections, Increased Risk of Death, Cancer, Major Cardiovascular Events, Blood Clots See on this page: Questions to Consider > Insurance Comparison Chart > Health Insurance Terms and Definitions > RINVOQ Complete is here to help you understand the Open Enrollment An annual period during which people can enroll in a group-sponsored health insurance plan for the next year. process. Below are a few questions to get you started and a health Insurance Comparison Chart to help you select the best option for you. You’ll also find definitions for common health insurance terms. These resources can help you when considering your health insurance options or when discussing them with your HR or benefits manager. An annual period during which people can enroll in a group-sponsored health insurance plan for the next year. Get personalized support Since every health insurance plan is different, you’ve got Insurance Specialists ready to tell you what to consider when you review your options. Your RINVOQ Complete Ambassador* can help out too. Just call 1.800.2RINVOQ (1.800.274.6867). QUESTIONS TO CONSIDER Is my treatment covered under this health insurance plan’s formulary The list of medicines that your health insurance plan will pay for or cover. ? Will my treatment require prior authorization Your health care provider must provide additional information to your health insurance company before they’ll cover a service or medication. under this health insurance plan? Will I be required to get my prescription from a Specialty Pharmacy A pharmacy that distributes medications with special storage and handling requirements, as well as other complexities. under this health insurance plan? Does this health insurance plan have an annual limit The maximum amount your health insurance will pay for the year. You’re required to pay all costs after you reach the annual limit. on benefits it pays for? If so, what is it? Does this health insurance plan have a lifetime limit A cap on the total benefits you may receive from your health insurance plan in your lifetime. that it will pay? If so, what is it? The list of medicines that your health insurance plan will pay for or cover. Your health care provider must provide additional information to your health insurance company before they’ll cover a service or medication. A pharmacy that distributes medications with special storage and handling requirements, as well as other complexities. The maximum amount your health insurance will pay for the year. You’re required to pay all costs after you reach the annual limit. A cap on the total benefits you may receive from your health insurance plan in your lifetime. Make sense of health insurance terms Annual Limit The maximum amount your health insurance will pay for the year. You’re required to pay all costs after you reach the annual limit. Benefits Verification (BV) A process that confirms your benefits and eligibility or your health insurance coverage for a prescription or medical service. Co-insurance A percentage of a prescription or a medical service that you pay after meeting your deductible. Co-pay A fixed amount you pay for a doctor’s visit, prescription, or other medical service. Co-pay Savings Card This card is used to lower your health insurance co-pay, or out-of-pocket costs, for a prescription medication. Deductible The amount you pay for health care services before your health insurance starts paying. Explanation of Benefits (EOB) A statement from your health insurance administrator that details what charges are eligible for benefits under your plan. Formulary The list of medicines that your health insurance plan will pay for or cover. Health Savings Account (HSA) An account that allows you to set aside pre-tax dollars to pay for yearly health care expenses. To be eligible to open an HSA, you must have a high-deductible health insurance plan. High-deductible Health Insurance Plan A plan that has a higher deductible than a traditional health insurance plan. This means you pay a greater amount each year before your medical expenses are covered. But typically, your yearly premium is lower. Lifetime Limit A cap on the total benefits you may receive from your health insurance plan in your lifetime. Open Enrollment An annual period during which people can enroll in a group-sponsored health insurance plan for the next year. Out-of-pocket Costs If using health insurance, out-of-pocket costs are the share of prescription drug costs you are responsible to pay, such as co-insurance, co-pay, or deductible. Out-of-pocket Maximum The most you’ll pay in medical expenses in a year before you’re fully covered. Pharmacy Benefit Covers prescription drugs that are usually self-administered, such as oral, injectable, or in other ways taken outside the physician’s office. Premium The amount you pay for health insurance every month. Prior Authorization (PA) Your health care provider must provide additional information to your health insurance company before they’ll cover a service or medication. Specialty Pharmacy A pharmacy that distributes medications with special storage and handling requirements, as well as other complexities. Can’t find what you’re looking for? Reach out to an Insurance Specialist at 1.800.2RINVOQ (1.800.274.6867) or call your Ambassador. *Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals. USES RINVOQ is a prescription medicine used to treat: * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. * Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with moderate to severe Crohn’s disease (CD) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn’s disease. * Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. IMPORTANT SAFETY INFORMATION What is the most important information I should know about RINVOQ? RINVOQ may cause serious side effects, including: * Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster). * Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor. * Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen. * Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker. * Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor. * Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away. * Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting. * Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results. Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients. What should I tell my HCP BEFORE starting RINVOQ? Tell your HCP if you: * Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as: * - Fever, sweating, or chills * - Shortness of breath * - Warm, red, or painful skin or sores on your body * - Muscle aches * - Feeling tired * - Blood in phlegm * - Diarrhea or stomach pain * - Cough * - Weight loss * - Burning when urinating or urinating more often than normal * Have TB or have been in close contact with someone with TB. * Are a current or past smoker. * Have had a heart attack, other heart problems, or stroke. * Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines. * Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system. * Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP. * Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines. * Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose. * There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110. * Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects. Especially tell your HCP if you take: * Medicines for fungal or bacterial infections * Rifampicin or phenytoin * Medicines that affect your immune system If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist. What should I avoid while taking RINVOQ? Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects. What should I do or tell my HCP AFTER starting RINVOQ? * Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. * Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: * - Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back * - Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw * - Pain or discomfort in your arms, back, neck, jaw, or stomach * - Shortness of breath with or without chest discomfort * - Breaking out in a cold sweat * - Nausea or vomiting * - Feeling lightheaded * - Weakness in one part or on one side of your body * - Slurred speech * Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including: * - Swelling * - Pain or tenderness in one or both legs * - Sudden unexplained chest or upper back pain * - Shortness of breath or difficulty breathing * * * Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits. What are other possible side effects of RINVOQ? Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis). A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ. Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your healthcare provider. These are not all the possible side effects of RINVOQ. How should I take RINVOQ? RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. This is the most important information to know about RINVOQ. For more information, talk to your HCP. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. USES RINVOQ is a prescription medicine used to treat: * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. * Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease. * Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. US-RNQ-220259 Please see the Full Prescribing Information, including the Medication Guide, for RINVOQ. Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have any questions about AbbVie's RINVOQ.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient. RINVOQ (UPADACITINIB) * Moderate to Severe Eczema (Atopic Dermatitis) * Moderate to Severe Rheumatoid Arthritis * Active Psoriatic Arthritis * Active Ankylosing Spondylitis * Active Non-radiographic Axial Spondyloarthritis * Moderate to Severe Ulcerative Colitis * Moderate to Severe Crohn’s Disease * RINVOQ Complete * Cost & Savings IMPORTANT INFORMATION FOR PATIENTS * Important Safety Information * Medication Guide * Full Prescribing Information (English) INFORMATION FROM ABBVIE * Healthcare Professionals Site * COVID-19 Information * Accessibility Statement * Contact Us * Terms of Use * Privacy Notice * Cookies Settings * Your Privacy Choices RINVOQ Complete Savings Card Terms and Conditions ‡Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy. US-RNQ-210272 US HEALTHCARE PROFESSIONALS ONLY You are about to enter a site that is for US healthcare professionals only. By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals section of this site. Products or treatments described on this site are available in the US but may not be available in all other countries. I am a licensed healthcare professional and wish to proceed to the healthcare professionals section of this site. Yes No US-RNQ-220499 LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? Yes No US-RNQ-220499 LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? Yes No US-RNQR-220513 US HEALTHCARE PROFESSIONALS ONLY You are about to enter a site that is for US healthcare professionals only. By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals section of this site. Products or treatments described on this site are available in the US but may not be available in all other countries. I am a licensed healthcare professional and wish to proceed to the healthcare professionals section of this site. Yes No US-RNQ-220010 LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? Yes No US-RNQ-220499 US HEALTHCARE PROFESSIONALS ONLY You are about to enter a site that is for US healthcare professionals only. By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals section of this site. Products or treatments described on this site are available in the US but may not be available in all other countries. I am a licensed healthcare professional and wish to proceed to the healthcare professionals section of this site. Yes No US-RNQ-220499 TERMS AND CONDITIONS AbbVie Inc. is providing this service to help patients find rheumatologists in their area who have experience with RINVOQ (upadacitinib). No fees have been received by or paid to rheumatologists for inclusion in this specialist locator directory. Inclusion of a physician in this directory does not represent an endorsement by or a recommendation from AbbVie Inc., nor does it imply that the rheumatologists on the list will determine that RINVOQ is right for you. You are ultimately responsible for the selection of a physician and it is an important decision that you should consider carefully. This rheumatologist locator tool is just one source of information available to you. AbbVie Inc. is the maker and marketer of RINVOQ (upadacitinib). Close US-RNQR-210387 IMPORTANT SAFETY INFORMATION What is the most important information I should know about RINVOQ? RINVOQ may cause serious side effects, including: * Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster). * Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor. * Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen. * Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker. * Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor. * Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away. * Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting. * Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results. Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients. What should I tell my HCP BEFORE starting RINVOQ? Tell your HCP if you: * Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as: * - Fever, sweating, or chills * - Shortness of breath * - Warm, red, or painful skin or sores on your body * - Muscle aches * - Feeling tired * - Blood in phlegm * - Diarrhea or stomach pain * - Cough * - Weight loss * - Burning when urinating or urinating more often than normal * Have TB or have been in close contact with someone with TB. * Are a current or past smoker. * Have had a heart attack, other heart problems, or stroke. * Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines. * Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system. * Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP. * Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines. * Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose. * There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110. * Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects. Especially tell your HCP if you take: * Medicines for fungal or bacterial infections * Rifampicin or phenytoin * Medicines that affect your immune system If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist. What should I avoid while taking RINVOQ? Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects. What should I do or tell my HCP AFTER starting RINVOQ? * Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. * Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: * - Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back * - Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw * - Pain or discomfort in your arms, back, neck, jaw, or stomach * - Shortness of breath with or without chest discomfort * - Breaking out in a cold sweat * - Nausea or vomiting * - Feeling lightheaded * - Weakness in one part or on one side of your body * - Slurred speech * Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including: * - Swelling * - Pain or tenderness in one or both legs * - Sudden unexplained chest or upper back pain * - Shortness of breath or difficulty breathing * * * Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits. What are other possible side effects of RINVOQ? Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis). A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ. Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your healthcare provider. These are not all the possible side effects of RINVOQ. How should I take RINVOQ? RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. This is the most important information to know about RINVOQ. For more information, talk to your HCP. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. USES RINVOQ is a prescription medicine used to treat: * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. * Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease. * Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. US-RNQ-220259 Please see the Full Prescribing Information, including the Medication Guide, for RINVOQ. Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have any questions about AbbVie's RINVOQ.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient. LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? Yes No US-RNQG-230183 LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? US-RNQR-190268 LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? Yes No US-RNQR-220513 YOU ARE NOW LEAVING THE RINVOQ WEBSITE By clicking “Agree and continue” below, you acknowledge and agree that AbbVie does not, in any way, endorse or recommend Doctor.com, the qualifications of any physician associated with Doctor.com, or the quality of medical care any of those physicians can provide. Please be aware that Doctor.com may have its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. If you agree to the above, click “Agree and continue” to proceed to Doctor.com. If you do not agree to the above, click “Cancel” to remain on RINVOQ.com. Agree and continue Cancel US-RNQR-220513 LEAVING ABBVIE WEB SITE You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility. Conversely, the presence of this link does not imply the linked site's endorsement of RINVOQ.com or AbbVie. Do you wish to leave this site? Yes No US-RNQR-221299 US HEALTHCARE PROFESSIONALS ONLY You are about to enter a site that is for US healthcare professionals only. By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals section of this site. Products or treatments described on this site are available in the US but may not be available in all other countries. I am a licensed healthcare professional and wish to proceed to the healthcare professionals section of this site. Yes No US-RNQ-220010 US HEALTHCARE PROFESSIONALS ONLY You are about to enter a site that is for US healthcare professionals only. By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals section of this site. Products or treatments described on this site are available in the US but may not be available in all other countries. I am a licensed healthcare professional and wish to proceed to the healthcare professionals section of this site. Yes No US-RNQ-220010 IMPORTANT SAFETY INFORMATION & USES Warning: Serious Infections, Increased Risk of Death, Cancer, Major Cardiovascular Events, Blood Clots IMPORTANT SAFETY INFORMATION & USES Warning: Serious Infections, Increased Risk of Death, Cancer, Major Cardiovascular Events, Blood Clots IMPORTANT SAFETY INFORMATION & USES Warning: Serious Infections, Increased Risk of Death, Cancer, Major Cardiovascular Events, Blood Clots IMPORTANT SAFETY INFORMATION & USES Warning: Serious Infections, Increased Risk of Death, Cancer, Major Cardiovascular Events, Blood Clots USES RINVOQ is a prescription medicine used to treat: * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. * Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with moderate to severe Crohn’s disease (CD) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn’s disease. * Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. IMPORTANT SAFETY INFORMATION What is the most important information I should know about RINVOQ? RINVOQ may cause serious side effects, including: * Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster). * Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor. * Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen. * Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker. * Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor. * Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away. * Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting. * Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results. Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients. What should I tell my HCP BEFORE starting RINVOQ? Tell your HCP if you: * Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as: * - Fever, sweating, or chills * - Shortness of breath * - Warm, red, or painful skin or sores on your body * - Muscle aches * - Feeling tired * - Blood in phlegm * - Diarrhea or stomach pain * - Cough * - Weight loss * - Burning when urinating or urinating more often than normal * Have TB or have been in close contact with someone with TB. * Are a current or past smoker. * Have had a heart attack, other heart problems, or stroke. * Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines. * Have other medical conditions, including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system. * Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP. * Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines. * Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose. * There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110. * Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects. Especially tell your HCP if you take: * Medicines for fungal or bacterial infections * Rifampicin or phenytoin * Medicines that affect your immune system If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist. What should I avoid while taking RINVOQ? Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects. What should I do or tell my HCP AFTER starting RINVOQ? * Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. * Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: * - Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back * - Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw * - Pain or discomfort in your arms, back, neck, jaw, or stomach * - Shortness of breath with or without chest discomfort * - Breaking out in a cold sweat * - Nausea or vomiting * - Feeling lightheaded * - Weakness in one part or on one side of your body * - Slurred speech * Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including: * - Swelling * - Pain or tenderness in one or both legs * - Sudden unexplained chest or upper back pain * - Shortness of breath or difficulty breathing * * * Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits. What are other possible side effects of RINVOQ? Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis). A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ. Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your healthcare provider. These are not all the possible side effects of RINVOQ. How should I take RINVOQ? RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. This is the most important information to know about RINVOQ. For more information, talk to your HCP. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. USES RINVOQ is a prescription medicine used to treat: * Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. * Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. * Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. * Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease. * Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. US-RNQ-220259 Please see the Full Prescribing Information, including the Medication Guide, for RINVOQ. Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have any questions about AbbVie's RINVOQ.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient. AbbVie may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, “cookies”). We use this data for multiple purposes, including for online targeted advertising (advertisements based on your interests inferred from your activity across other unaffiliated sites and services) and website analytics purposes, as well as to personalize content, save your preferences, provide social media features, and track the site’s performance, as further described in the"Cookies and similar tracking and data collection technologies" section of our Privacy Notice. We retain this data for as long as necessary to fulfill these purposes or as needed to comply with our record retention obligations. We do not sell your data, but we may disclose it to our marketing and advertising partners for purposes of online targeted advertising or for website analytics purposes. To opt out of the use or disclosure of your cookie-based personal data for online targeted advertising or for website analytics purposes, or to otherwise manage your preferences, please click on Cookie Settings below. For additional information on the categories of data we collect, the purposes for their collection, disclosures to third parties, and data retention, please visit ourPrivacy Notice. Cookies Settings PRIVACY PREFERENCE CENTER You can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Depending on the jurisdiction where you live, you may have the right to opt out of the use and disclosure of your personal data for purposes of online targeted advertising (advertisements based on your interests inferred from your activity across other unaffiliated sites and services) or website analytics (to understand website usage behavior and receive website analytics). To opt out of the use and disclosure of your cookie-based personal data for these purposes, you can toggle off “Functional” (for website analytics) and/or “Advertising” (for online targeted advertising) below. To opt out of the use and disclosure of your non-cookie-based information for online targeted advertising purposes, please also click"Your Privacy Choices" on our website. Note that if we recognize your Global Privacy Control (GPC) as enabled, our policy is to opt you out of the use or disclosure of your cookie-based personal data for online targeted advertising and website analytics purposes for the browser or device on which you have GPC enabled. However, unless you are logged in to an AbbVie account that has the capability to link the personal data we have about you to your browser or device, we cannot apply your GPC opt-out request to your non-cookie based personal data because the connection between your browser or device is not known to us. Thus, if you have GPC enabled, please click"Your Privacy Choices" to opt out of the disclosure of your non-cookie based personal data for these purposes. MANAGE CONSENT PREFERENCES REQUIRED COOKIES Always Active These cookies are necessary for the website to function and cannot be switched off in our systems. They may be set by us or by third party providers whose services we have added to our pages. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. View Vendor Details FUNCTIONAL COOKIES Functional Cookies These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They may be set by us or by third party providers whose services we have added to our pages. They help us to know which pages are the most and least popular and see how visitors move around the site. View Vendor Details ADVERTISING COOKIES Advertising Cookies These cookies may be set through our site by our advertising partners to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising, but you will still receive online advertising. View Vendor Details Back Button PERFORMANCE COOKIES Search Icon Filter Icon Clear checkbox label label Apply Cancel Consent Leg.Interest checkbox label label checkbox label label checkbox label label * View Cookies * Name cookie name Confirm My Choices Live chat:Chat Live 24/7